Thursday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the SUPERNOVA Phase 3 COVID-19 pre-exposure prophylaxis (prevention) trial. The study showed AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in immunocompromised patients. The trial met both dual primary endpoints: Relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant and the relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation.  SUPERNOVA demonstrated the potential benefit ...